Skip to main content

Advertisement

SpringerLink
Log in

A retrospective review of patients with urothelial cancer in 3,370 recipients after renal transplantation: a single-center experience

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objective

To summarize the diagnosis, surgical intervention and postoperative management of patients with urothelial cancer (UC) after renal transplants (RTx).

Methods

In our retrospective review of 3,370 RTx recipients in our transplant center from 1974 to 2012, all recipients underwent routine checkups and follow-up. Imaging was performed in all patients suspected of having malignancies, and the histological cell type of the specimen slices was reappraised by pathologists. The data of all recipients with malignancies were retrospectively reviewed to determine clinical characteristics after RTx.

Results

A total of 169 patients of the cohort of 3,370 had malignancies after RTx. Of 180 tumors, 106 tumors were confirmed as UC. Fifty-two patients had taken drugs containing aristolochic acid. The median time to neoplasia after RTx in the group taking aristolochic acid (30 months) was significantly less than in those not taking aristolochic acid (60.3 months). We recommended surgical intervention for RTx recipients with UC, transurethral resection of bladder tumors for patients with solitary or concomitant superficial UC, and radical cystectomy for high-risk bladder UC. We performed simultaneous bilateral or unilateral nephroureterectomy in patients with upper urinary tract UC.

Conclusion

Our results suggest that UC is the predominant tumor in Chinese RTx recipients and that regular urinalysis and imaging are needed in all recipients after RTx, especially women with a history of taking aristolochic acid. Surgical interventions did not increase the risk beyond that in UC patients without RTx.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. La Manna G, Corsini S, Iannelli S, Cappuccilli ML, Comai G, Iorio M, Todeschini P, Carretta E, Scolari MP, Bontadini A, Stefoni S (2013) Influence of the immunogenetic KIR and HLA systems on long-term renal transplant outcome. Ann Transpl 18:611–621

    Article  Google Scholar 

  2. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y (2007) Cancer incidence among Canadian kidney transplant recipients. Am J Transpl 7(4):941–948

    Article  CAS  Google Scholar 

  3. Sheil AG, Disney AP, Mathew TH, Livingston BE, Keogh AM (1997) Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transpl Proc 29(1–2):825–827

    Article  CAS  Google Scholar 

  4. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frödin L (1995) Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 60(2):183–189

    Article  CAS  PubMed  Google Scholar 

  5. Penn I (1994) Malignancy. Surg Clin North Am 74(5):1247–1257

    CAS  PubMed  Google Scholar 

  6. Penn I (2000) Cancers in renal transplant recipients. Adv Ren Replace Ther 7(2):147–156

    CAS  PubMed  Google Scholar 

  7. Vogt P, Frei U, Repp H, Bunzendahl H, Oldhafer K, Pichlmayr R (1990) Malignant tumor in renal transplant recipients receiving cyclosporine: survey of 598 first-kidney transplantation. Nephrol Dial Transplant 5(4):282–288

    Article  CAS  PubMed  Google Scholar 

  8. Ochiai T, Asano T, Isono K (1987) Development of malignancies in Japanese renal transplant recipients. Transplant Proc 19(2):2967–2970

    CAS  PubMed  Google Scholar 

  9. Buzzeo BD, Heisey DM, Messing EM (1997) Bladder cancer in renal transplant recipients. Urology 50(4):525–528

    Article  CAS  PubMed  Google Scholar 

  10. Feng WW, Wang TN, Chen HC, Ho JC, Ko YC (2007) Malignancies after renal transplantation in southern Taiwan: experience in one centre. BJU Int 99(4):825–829

    Article  PubMed  Google Scholar 

  11. Wu MJ, Lian JD, Yang CR, Cheng CH, Chen CH, Lee WC, Shu KH, Tang MJ (2004) High cumulative incidence of urinary tract urothelial cancer after kidney transplantation in Taiwan. Am J Kidney Dis 43(6):1091–1097

    Article  PubMed  Google Scholar 

  12. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD (2008) Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 15(1):53–57

    Article  CAS  PubMed  Google Scholar 

  13. Melchior S, Franzaring L, Shardan A, Schwenke C, Plümpe A, Schnell R, Dreikorn K (2011) Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol 185(2):428–432

    Article  PubMed  Google Scholar 

  14. Penn I (1987) Cancer following cyclosporine therapy. Transplantation 43(1):32–35

    Article  CAS  PubMed  Google Scholar 

  15. Galve ML, Cuervas-Mons V, Figueras J, Herrero I, Mata M, Clemente G, Prieto M, Margarit C, Bernardos A, Casafont F (1999) Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc 31(1–2):1275–1277

    Article  CAS  PubMed  Google Scholar 

  16. Yokota K, Fukumitsu M, Kuzuhara K, Otsubo O, Tomikawa S, Nagao T, Uchida H, Sato K, Nakayama Y, Endo T (1994) Development of cancer in renal allograft recipients. Transplant Proc 26(4):1977–1978

    CAS  PubMed  Google Scholar 

  17. Jin DC, Yoon YS, Yoou SA (1994) Ten cases of malignancies in kidney allograft. Transpl Proc 26(4):1975–1978

    CAS  Google Scholar 

  18. Rogers A, Ng JK, Glendinning J, Rix D (2012) The management of transitional cell carcinoma (TCC) in a European regional renal transplant population. BJU Int 110(2 Pt B):E34–E40

    Article  PubMed  Google Scholar 

  19. Liao CH, Chueh SC, Lai MK, Chen J (2004) Transitional cell carcinoma in renal transplant recipients. Transpl Proc 36(7):2152–2153

    Article  Google Scholar 

  20. Kao YL, Ou YC, Yang CR, Ho HC, Su CK, Shu KH (2003) Transitional cell carcinoma in renal transplant recipients. World J Surg 27(8):912–916

    Article  PubMed  Google Scholar 

  21. Yuan M, Shi YB, Li ZH, Xia M, Ji GZ, Xu GX, Han Y (2009) De novo urothelial carcinoma in kidney transplant patients with end-stage aristolochic acid nephropathy in China. Transpl Proc 41(5):1619–1623

    Article  CAS  Google Scholar 

  22. Stiborová M, Frei E, Hodek P, Wiessler M, Schmeiser HH (2005) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113(2):189–197

    Article  PubMed  Google Scholar 

  23. Stiborová M, Frei E, Schmeiser HH, Arlt VM, Martínek V (2014) Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: experimental and theoretical approaches. Int J Mol Sci 15(6):10271–10295

    Article  PubMed Central  PubMed  Google Scholar 

  24. Hou HJ, Xiao J, Tian Y (2013) Contralateral nephroureterectomy for renal transplant recipients with unilateral upper urinary tract transitional cell carcinoma: a report of 12 cases. Transplant Proc 45(6):2203–2206

    Article  CAS  PubMed  Google Scholar 

  25. Javaid MM, Chowdhury S, Henderson A, Olsburgh J (2013) Advanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agent. Clin Nephrol 79(2):154–160

    Article  PubMed  Google Scholar 

  26. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS (2013) Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 119(17):3219–3227

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China

    Aiying Zhang, Donghao Shang, Jian Zhang, Lei Zhang, Rui Shi, Fengqi Fu & Ye Tian

Authors
  1. Aiying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donghao Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fengqi Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ye Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ye Tian.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, A., Shang, D., Zhang, J. et al. A retrospective review of patients with urothelial cancer in 3,370 recipients after renal transplantation: a single-center experience. World J Urol 33, 713–717 (2015). https://doi.org/10.1007/s00345-014-1412-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1412-4

Keywords

Search

Navigation